MIMEDX to Host Fourth Quarter and Full Year 2022 Operating and Financial Results Conference Call on February 28
February 15, 2023 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., Feb. 15, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it will report...
MIMEDX Appoints Joseph H. Capper as Chief Executive Officer and Director
January 30, 2023 08:00 ET
|
MiMedx Group, Inc
Highly experienced and accomplished three-time healthcare CEO with a proven track record of substantial value creation to lead MIMEDX MARIETTA, Ga., Jan. 30, 2023 (GLOBE NEWSWIRE) -- MiMedx Group,...
MIMEDX Confirms Fourth Quarter and Full Year 2022 Net Sales Expectations, Comments on Evolving Medicare Reimbursement Landscape and Provides Corporate Updates
January 09, 2023 08:02 ET
|
MiMedx Group, Inc
Fourth quarter and full year 2022 net sales expected in the ranges of $73 million to $76 million and $266 million to $269 million, respectively Provides commentary regarding the potential impact of...
MIMEDX Announces Commercial Launch of EPIFIX® in Japan with Exclusive Distribution Agreement with GUNZE MEDICAL LIMITED
January 04, 2023 16:01 ET
|
MiMedx Group, Inc
MIMEDX aligns with a leading distributor of wound care products in Japan to capitalize on first-mover advantage for EPIFIX MARIETTA, Ga. and OSAKA, Japan, Jan. 04, 2023 (GLOBE NEWSWIRE) -- MiMedx...
MIMEDX Appoints Ricci S. Whitlow as Chief Operating Officer
January 03, 2023 08:00 ET
|
MiMedx Group, Inc
MIMEDX bolsters management team with 30+ year MedTech veteran with extensive operational leadership MARIETTA, Ga., Jan. 03, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or...
MIMEDX Announces Wound & Surgical Product Pipeline Expansion via In-Licensing and Distribution Agreement with Turn Therapeutics
December 08, 2022 08:00 ET
|
MiMedx Group, Inc
Agreement provides MIMEDX with exclusive rights to Turn’s PermaFusion® proprietary antimicrobial intellectual property (IP), accelerating the product development pipeline for wound and surgical...
MIMEDX to Present at Upcoming Investor Conferences
November 10, 2022 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., Nov. 10, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that senior management...
MIMEDX Announces Third Quarter 2022 Operating and Financial Results
November 02, 2022 16:15 ET
|
MiMedx Group, Inc
Third Quarter Net Sales of $67.7 Million Reflect Growth of 7.3% Introducing Wound & Surgical and Regenerative Medicine Segment Reporting to Highlight Trends Within Each Business Unit Third...
MIMEDX to Host Third Quarter 2022 Operating and Financial Results Conference Call on November 2
October 19, 2022 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., Oct. 19, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report...
MIMEDX Appoints Matt Notarianni as Head of Investor Relations
October 04, 2022 08:00 ET
|
MiMedx Group, Inc
Experienced Healthcare-focused Financial and Communications Leader to Strengthen and Expand Relationships with Investment Community MARIETTA, Ga., Oct. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group,...